Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.

British journal of haematology - 1 Dec 2024

Kim Dong Hyun, Kim Seokhyeon, Park Seonyang, Byun Ja Min, Hong Junshik, Shin Dong-Yeop, Kim Inho, Bang Soo Mee, Lee Jeong-Ok, Lee Ji Yun, Kim Sang-A, Kim Ki Hwan, Chung Yeun-Jun, Jung Seung-Hyun, Koh Youngil, Yoon Sung-Soo

Abstract excerpt

The role of imatinib in PDGFRA/B-negative hypereosinophilic syndromes (HES) is controversial because of the heterogeneity of HES and the scarcity of prospective studies. We conducted a phase II clinical trial to evaluate the efficacy of imatinib in PDGFRA/B-negative HES. Thirty-two patients were treated with imatinib (100-400 mg daily), and the molecular basis of their response was identified using whole-exome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypereosinophilic Syndrome

Share to Imatinib Mesylate

Share to Mutation

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39389908
DOI: 10.1111/bjh.19828
PMCID: PMC11637721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of imatinib mesylate in patients with PDGFRA/B-negative hypereosinophilic syndrome.PMID 39389908Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.Semantic proximity Read ↗

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.Semantic proximity Read ↗

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaSemantic proximity Read ↗

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome SequencingSemantic proximity Read ↗

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndromeSemantic proximity Read ↗

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like diseaseSemantic proximity Read ↗

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutationSemantic proximity Read ↗

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.